유료기사는 인쇄용 화면을 제공하지 않습니다.

AriBio Lab, Soar...HLB Therapeutics Hits Lower Limit[K-Bio Bulse]

  • created on 11/17/2026 6:00:12 AM
  • modified on 11/17/2026 6:00:12 AM
This article was released as Pharm Edaily Premium Content on 11/17/2026 6:00:12 AM Subscribe
Unauthorized reproduction or distribution is illegal and subject to criminal penalties.
Pharm Edaily enforces a zero-tolerance policy and will take strict action.
[Stephen kim, Edaily Reporter] Korean pharma and biotech stocks diverged sharply on November 16 as investors reacted to clinical news.

Corestem ChemOn hit the daily upper limit after clarifying its US approval pathway, and AriBio Lab jumped more than 27% ahead of a key Alzheimer‘s readout from its affiliate. HLB Therapeutics fell by the daily limit after a US Phase 3 failure.

AriBio Lab stock trend (From naver stock)
AriBio Lab stock trend (From naver stock)
AriBio Lab surges 27% ahead of AR1001 Phase 3 results

According to KG Zeroin MP Doctor, AriBio Lab closed up 1,240 won (27.13%) at 5,810 won. That is more than triple its late-July low of 1,824 won.

The rally came ahead of results from affiliate AriBio’s global Phase 3 trial (POLARIS-AD) of AR1001 (mirodenafil), an oral Alzheimer‘s drug candidate. The results will be presented in the opening oral session of CTAD 2026 in Boston, expected early on November 17 Korea time. The trial enrolled 1,535 patients across 13 countries, and 1,348 of them completed 52 weeks of treatment. The results will decide whether AriBio files a New Drug Application with the FDA.

“Today’s gain appears to reflect tomorrow morning‘s topline announcement,” an AriBio official said. “Employees naturally have high expectations, but even at our level the outcome is still unknown.”

AR1001 is a PDE5 inhibitor that works through several mechanisms, including improving cerebral blood flow and protecting neurons. Leqembi and Kisunla are antibodies given by IV every two to four weeks. AR1001 is a once-daily pill with a lower risk of ARIA. AriBio has signed an option and license deal worth up to $4.7 billion with China’s Fosun Pharma.

Because AriBio is unlisted, investors are treating AriBio Lab, AriBio Holdings and Samjin Pharmaceutical as the stocks most directly exposed to the result.

Corestem ChemOn
Corestem ChemOn
Corestem ChemOn hits upper limit on FDA pathway

Corestem ChemOn rose 417 won (30.00%) to close at the upper limit of 1,807 won. It had fallen to 1,300 won early in the session.

The company said it had received the official minutes of its Type C meeting with the FDA on Neuronata-R (lenzumestrocel), its stem cell therapy for ALS. The FDA agreed to a new randomized, double-blind, placebo-controlled Phase 3b confirmatory trial. The company would then file a Biologics License Application (BLA).

The FDA raised no major objections to the proposed primary endpoint, the change in ALSFRS-R total score at week 24. It also said it is open to accepting data from trials run in Korea that meet ICH guidelines.

“The minutes have clarified our US approval path through a Phase 3b confirmatory trial,” CEO Yang Gil-an said.

HLB Therapeutics
HLB Therapeutics
HLB Therapeutics hits lower limit

HLB Therapeutics fell 700 won (29.98%) and stayed at the lower limit of 1,635 won for the whole session.

Its US subsidiary ReGenTree said the US Phase 3 trial (SEER-2) of RGN-259, an eye drop for neurotrophic keratitis, failed to reach statistical significance on its primary endpoint, the complete healing rate at four weeks. This is the candidate‘s second Phase 3 failure, after the European SEER-3 trial.

“We will thoroughly analyze the full data set and carefully review our future development plans,” CEO Ahn Ki-hong said.

저작권자 © 팜이데일리 - 기사 무단전재, 재배포시 법적인 처벌을 받을 수 있습니다.